Van Renterghem, B.; Wozniak, A.; Castro, P.G.; Franken, P.; Pencheva, N.; Sciot, R.; Schöffski, P.
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. Int. J. Mol. Sci. 2022, 23, 7493.
https://doi.org/10.3390/ijms23147493
AMA Style
Van Renterghem B, Wozniak A, Castro PG, Franken P, Pencheva N, Sciot R, Schöffski P.
Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. International Journal of Molecular Sciences. 2022; 23(14):7493.
https://doi.org/10.3390/ijms23147493
Chicago/Turabian Style
Van Renterghem, Britt, Agnieszka Wozniak, Patricia Garrido Castro, Patrick Franken, Nora Pencheva, Raf Sciot, and Patrick Schöffski.
2022. "Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma" International Journal of Molecular Sciences 23, no. 14: 7493.
https://doi.org/10.3390/ijms23147493
APA Style
Van Renterghem, B., Wozniak, A., Castro, P. G., Franken, P., Pencheva, N., Sciot, R., & Schöffski, P.
(2022). Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. International Journal of Molecular Sciences, 23(14), 7493.
https://doi.org/10.3390/ijms23147493
